Compare Stocks: XFOR, XNCR, NTLA, and MAZE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MAZE Maze Therapeutics	$28.53 +2.6%	$27.49	$12.81 ▼ $53.65	$1.54B	2.21	395,744 shs	231,105 shs
NTLA Intellia Therapeutics	$11.24 +2.5%	$13.69	$7.95 ▼ $28.25	$1.53B	1.81	4.32 million shs	4.33 million shs
XFOR X4 Pharmaceuticals	$4.17 +0.5%	$4.02	$1.35 ▼ $4.83	$391.43M	0.37	600,273 shs	447,777 shs
XNCR Xencor	$20.00 +0.8%	$15.52	$6.92 ▼ $21.96	$1.47B	0.85	1.08 million shs	996,652 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MAZE Maze Therapeutics	+2.59%	+3.26%	-13.12%	+9.60%	+100.21%
NTLA Intellia Therapeutics	+2.46%	+1.35%	-35.51%	-20.23%	-1.14%
XFOR X4 Pharmaceuticals	+0.48%	+4.25%	+5.84%	-5.87%	+163.92%
XNCR Xencor	+0.81%	-6.93%	+27.63%	+55.52%	+167.02%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MAZE Maze Therapeutics	$28.53 +2.6%	$27.49	$12.81 ▼ $53.65	$1.54B	2.21	395,744 shs	231,105 shs
NTLA Intellia Therapeutics	$11.24 +2.5%	$13.69	$7.95 ▼ $28.25	$1.53B	1.81	4.32 million shs	4.33 million shs
XFOR X4 Pharmaceuticals	$4.17 +0.5%	$4.02	$1.35 ▼ $4.83	$391.43M	0.37	600,273 shs	447,777 shs
XNCR Xencor	$20.00 +0.8%	$15.52	$6.92 ▼ $21.96	$1.47B	0.85	1.08 million shs	996,652 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MAZE Maze Therapeutics	+2.59%	+3.26%	-13.12%	+9.60%	+100.21%
NTLA Intellia Therapeutics	+2.46%	+1.35%	-35.51%	-20.23%	-1.14%
XFOR X4 Pharmaceuticals	+0.48%	+4.25%	+5.84%	-5.87%	+163.92%
XNCR Xencor	+0.81%	-6.93%	+27.63%	+55.52%	+167.02%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MAZE Maze Therapeutics	3.00	Buy	$66.00	131.34% Upside
NTLA Intellia Therapeutics	2.30	Hold	$20.19	79.60% Upside
XFOR X4 Pharmaceuticals	2.57	Moderate Buy	$9.70	132.61% Upside
XNCR Xencor	2.44	Hold	$24.86	24.29% Upside

Current Analyst Ratings Breakdown

Latest XFOR, XNCR, NTLA, and MAZE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2026	XNCR Xencor	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$19.00 ➝ $20.00
8/6/2026	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$26.00 ➝ $30.00
8/6/2026	XNCR Xencor	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$43.00 ➝ $44.00
7/30/2026	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$26.00
7/28/2026	XFOR X4 Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	NTLA Intellia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	NTLA Intellia Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Peer Perform ➝ Underperform	$9.00
7/10/2026	XFOR X4 Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/10/2026	XFOR X4 Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$11.00
7/10/2026	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$12.00 ➝ $17.00
7/10/2026	XFOR X4 Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$11.00

(Data available from 8/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MAZE Maze Therapeutics	$167.50M	9.43	N/A	N/A	$7.38 per share	3.87
NTLA Intellia Therapeutics	$67.67M	23.21	N/A	N/A	$5.80 per share	1.94
XFOR X4 Pharmaceuticals	$35.11M	11.20	N/A	N/A	$2.13 per share	1.96
XNCR Xencor	$125.58M	11.81	N/A	N/A	$8.90 per share	2.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MAZE Maze Therapeutics	-$131.12M	-$2.53	N/A	N/A	N/A	N/A	-36.62%	-31.78%	N/A
NTLA Intellia Therapeutics	-$412.69M	-$3.54	N/A	N/A	N/A	-597.04%	-57.47%	-46.24%	N/A
XFOR X4 Pharmaceuticals	-$79.20M	-$4.54	N/A	N/A	N/A	-1,106.30%	-94.90%	-48.09%	N/A
XNCR Xencor	-$91.92M	-$2.29	N/A	N/A	N/A	-155.59%	-27.58%	-19.75%	N/A

Latest XFOR, XNCR, NTLA, and MAZE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	NTLA Intellia Therapeutics	-$0.7993	-$0.80	-$0.0007	-$0.80	$12.98 million	$7.66 million
8/6/2026	Q2 2026	XFOR X4 Pharmaceuticals	-$0.1760	-$0.13	+$0.0460	-$0.13	$2.42 million	$8.81 million
8/5/2026	Q2 2026	XNCR Xencor	-$0.8015	-$0.29	+$0.5115	-$0.29	$18.89 million	$51.22 million
5/12/2026	Q1 2026	MAZE Maze Therapeutics	-$0.43	-$0.45	-$0.02	-$0.45	N/A	$20.00 million
5/11/2026	Q1 2026	NTLA Intellia Therapeutics	-$0.92	-$0.81	+$0.11	-$0.81	$13.81 million	$15.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MAZE Maze Therapeutics	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MAZE Maze Therapeutics	0.11	17.88	17.88
NTLA Intellia Therapeutics	N/A	6.10	6.10
XFOR X4 Pharmaceuticals	0.45	10.18	9.98
XNCR Xencor	N/A	6.57	6.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MAZE Maze Therapeutics	N/A
NTLA Intellia Therapeutics	88.77%
XFOR X4 Pharmaceuticals	72.03%
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
MAZE Maze Therapeutics	5.30%
NTLA Intellia Therapeutics	3.50%
XFOR X4 Pharmaceuticals	1.13%
XNCR Xencor	5.08%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MAZE Maze Therapeutics	121	55.35 million	52.41 million	N/A
NTLA Intellia Therapeutics	600	139.72 million	134.83 million	Optionable
XFOR X4 Pharmaceuticals	80	94.32 million	93.25 million	No Data
XNCR Xencor	280	74.14 million	70.38 million	Optionable

XFOR, XNCR, NTLA, and MAZE Headlines

Recent News About These Companies

Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of "Hold" by Brokerages

3 hours ago | americanbankingnews.com

Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Hold" by Brokerages

3 hours ago | marketbeat.com

Xencor Reports Second Quarter 2026 Financial Results

4 hours ago | aol.comA

Xencor (NASDAQ:XNCR) Price Target Raised to $30.00

August 6 at 11:48 AM | marketbeat.com

Xencor (NASDAQ:XNCR) Hits New 52-Week High Following Better-Than-Expected Earnings

August 6 at 10:19 AM | marketbeat.com

Xencor (NASDAQ:XNCR) Price Target Raised to $44.00 at Cantor Fitzgerald

August 6 at 8:23 AM | marketbeat.com

Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates

August 5 at 6:26 PM | zacks.com

Xencor (NASDAQ:XNCR) Releases Earnings Results, Beats Expectations By $0.51 EPS

August 5 at 6:10 PM | marketbeat.com

Xencor (NASDAQ:XNCR) Trading Down 3.9% - Here's Why

August 3, 2026 | marketbeat.com

Xencor’s XmAb412 Enters First-in-Human Testing: What Early-Stage Investors Should Watch

August 3, 2026 | tipranks.com

Xencor (NASDAQ:XNCR) Earns Outperform Rating from Wedbush

August 1, 2026 | americanbankingnews.com

Xencor (NASDAQ:XNCR) Reaches New 1-Year High - Should You Buy?

July 30, 2026 | marketbeat.com

Wedbush Reiterates Outperform Rating for Xencor (NASDAQ:XNCR)

July 30, 2026 | marketbeat.com

Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter

July 29, 2026 | finance.yahoo.com

Xencor (XNCR) Expected to Post Earnings on Wednesday

July 29, 2026 | marketbeat.com

EcoR1 Capital LLC Cuts Stock Holdings in Xencor, Inc. $XNCR

July 28, 2026 | marketbeat.com

Xencor (NASDAQ:XNCR) Stock Price Down 6.7% - Should You Sell?

July 22, 2026 | marketbeat.com

Xencor (NASDAQ:XNCR) Sets New 52-Week High - Should You Buy?

July 21, 2026 | marketbeat.com

Xencor (NASDAQ:XNCR) Sees Unusually-High Trading Volume - Here's Why

July 20, 2026 | marketbeat.com

Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?

July 20, 2026 | zacks.com

Xencor: Strong Buy, XmAb819 Presentation, And End Of 2026 XmAb942 Interim Data

July 19, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

XFOR, XNCR, NTLA, and MAZE Company Descriptions

Maze Therapeutics NASDAQ:MAZE

$28.53 +0.72 (+2.59%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$28.53 0.00 (0.00%)

As of 08/6/2026 06:13 PM Eastern

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. Our goal is to bring novel precision medicines to patients to maximize our impact on human health. CKD is a serious, progressive condition that affects approximately 37 million patients in the United States, where it is expected to be the fifth most prevalent chronic disease by 2040. Current treatments for CKD consider patients as falling into clinical categories and focus on slowing the progression of disease, but do not target the underlying genetic drivers of disease. Our lead programs are designed to phenocopy, or mimic, the protective effects of certain genetic variants that are associated with reduced disease burden and improved kidney function in distinct groups of CKD patients. Our most advanced lead program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD, which is estimated to affect over one million patients in the United States alone. Although the link between APOL1 variants and renal dysfunction has been known for over a decade, we have identified a new protective variant that underpins our therapeutic approach for MZE829 and may ultimately allow us to address a broader population of AKD than has previously been possible in the clinical setting. In October 2024, we reported results for our Phase 1 clinical trial of MZE829, in which we enrolled 111 healthy patients who received either single or multiple ascending doses of 20 mg to 480 mg of MZE829 administered daily. Treatment was well tolerated with no severe adverse events or serious adverse events reported in patients treated with single doses up to 480 mg and multiple doses of up to 350 mg daily for seven days. Dose-proportional pharmacokinetics, or PK, was observed with low variability (10-40%) across doses. We initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose our first patient in the first quarter of 2025 and to report proof of concept data in the first quarter of 2026. Our second lead program, MZE782, is an oral, small molecule inhibitor of the solute transporter SLC6A19, a novel CKD target, with the potential to address approximately five million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens or as an alternative option for those patients who do not adequately respond to today’s standard of care. We initiated a Phase 1 trial of MZE782 in September 2024 and expect to report initial data from this trial in the second half of 2025. In addition to CKD, we believe MZE782 may provide benefit to patients suffering from the genetically defined metabolic disease, phenylketonuria, or PKU. Following our ongoing Phase 1 trial of MZE782, we plan to conduct a parallel Phase 2 clinical trial to explore MZE782 as a potential treatment of PKU. Our Compass platform supports end-to-end variant identification and functionalization capabilities as well as advanced research tools and methodologies for drug development. We believe the process of variant functionalization, or understanding how genetic variants function to affect the course of disease, is a foundational aspect of precision medicine and one of the core capabilities that sets us apart from others in the field. We were incorporated under the laws of the State of Delaware on August 29, 2017, originally under the name Genetic Modifiers NewCo, Inc. We changed our name on July 5, 2018 to Modulus Therapeutics, Inc. and on September 25, 2018, to Maze Therapeutics, Inc. Our principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California.

Intellia Therapeutics NASDAQ:NTLA

$11.24 +0.27 (+2.46%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$11.61 +0.37 (+3.26%)

As of 06:03 AM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

X4 Pharmaceuticals NASDAQ:XFOR

$4.17 +0.02 (+0.48%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$4.14 -0.04 (-0.84%)

As of 05:34 AM Eastern

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

Xencor NASDAQ:XNCR

$20.00 +0.16 (+0.81%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$19.85 -0.15 (-0.75%)

As of 05:35 AM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XFOR, XNCR, NTLA, and MAZE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XFOR, XNCR, NTLA, and MAZE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XFOR, XNCR, NTLA, and MAZE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

XFOR, XNCR, NTLA, and MAZE Company Descriptions

Maze Therapeutics NASDAQ:MAZE

Intellia Therapeutics NASDAQ:NTLA

X4 Pharmaceuticals NASDAQ:XFOR

Xencor NASDAQ:XNCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XFOR, XNCR, NTLA, and MAZE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XFOR, XNCR, NTLA, and MAZE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XFOR, XNCR, NTLA, and MAZE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

XFOR, XNCR, NTLA, and MAZE Company Descriptions

Maze Therapeutics NASDAQ:MAZE

Intellia Therapeutics NASDAQ:NTLA

X4 Pharmaceuticals NASDAQ:XFOR

Xencor NASDAQ:XNCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools